WuXi Biologics has signed an acquisition agreement to take over a Bayer’s drug product manufacturing plant in Leverkusen, Germany.

The Leverkusen plant will be the Chinese firm’s first drug product facility in Europe bolstering its commercial manufacturing capabilities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As agreed, WuXi Biologics Germany will assume the operations of the plant and purchase the associated equipment. It has also entered into a long-term lease contract for the building.

WuXi Biologics CEO Dr Chris Chen said: “We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high-quality drug product manufacturing capacities and capabilities.

“Our business in the EU, US and China market has experienced robust growth in the past few years. This additional drug product plant further confirms our commitment to ‘Global Dual Sourcing within WuXi Biologics’ strategy.

“WuXi Biologics will continue to expand our worldwide capacity, providing global partners with a robust and premier-quality supply chain network to benefit patients worldwide.”

T plant will serve as a back-up site for manufacturing Bayer’s Kovaltry, an antihemophilic factor (recombinant).

Subject to customary closing conditions, the transaction is expected to close in the following months.

Furthermore, WuXi Biologics signed an agreement in 2018 to develop a biologics drug substance manufacturing facility in Dundalk, Ireland.

The Chinese firm invested around €325m to develop the facility, set to attain full production next year.